R L Vessella
Overview
Explore the profile of R L Vessella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
2496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paul P, Raghu D, Chan A, Gulati T, Lambeth L, Takano E, et al.
Oncogene
. 2016 Sep;
35(48):6235-6245.
PMID: 27641331
Restoration of tumor suppression is an attractive onco-therapeutic approach. It is particularly relevant when a tumor suppressor is excessively degraded by an overactive oncogenic E3 ligase. We previously discovered that...
2.
Li Y, Hwang T, Oseth L, Hauge A, Vessella R, Schmechel S, et al.
Oncogene
. 2012 Jan;
31(45):4759-67.
PMID: 22266865
Reactivation of the androgen receptor (AR) during androgen depletion therapy (ADT) underlies castration-resistant prostate cancer (CRPCa). Alternative splicing of the AR gene and synthesis of constitutively active COOH-terminally truncated AR...
3.
Bryant R, Pawlowski T, Catto J, Marsden G, Vessella R, Rhees B, et al.
Br J Cancer
. 2012 Jan;
106(4):768-74.
PMID: 22240788
Background: The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for the diagnosis, staging and prediction of outcome in...
4.
Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, et al.
Oncogene
. 2011 Dec;
31(35):3939-48.
PMID: 22139082
A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome,...
5.
Urbanucci A, Sahu B, Seppala J, Larjo A, Latonen L, Waltering K, et al.
Oncogene
. 2011 Sep;
31(17):2153-63.
PMID: 21909140
Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression on the chromatin binding of the receptor...
6.
Vessella R, Wilbur D, Buhler K, Lange P
Methods Mol Med
. 2011 Feb;
53:217-42.
PMID: 21318798
Metastatic renal cell carcinoma (RCC) is incurable and there are few treatment options that assure even a short prolongation in survival. It is the most common malignancy of the adult...
7.
Koreckij T, Nguyen H, Brown L, Yu E, Vessella R, Corey E
Br J Cancer
. 2009 Jul;
101(2):263-8.
PMID: 19603032
Background: Dasatinib is a small molecule kinase inhibitor that has recently been shown to inhibit Src family kinases (SFK) and also has activity against CaP. Of importance to metastatic CaP,...
8.
Maki H, Saramaki O, Shatkina L, Martikainen P, Tammela T, van Weerden W, et al.
J Pathol
. 2007 May;
212(4):395-401.
PMID: 17503439
BAG-1L (Bcl-2-associated anthanogene 1) has been found to interact with androgen receptor (AR), and has been suggested to be involved in the development of prostate cancer. In order to determine...
9.
Chen C, Sun X, Guo P, Dong X, Sethi P, Zhou W, et al.
Oncogene
. 2006 Oct;
26(16):2386-94.
PMID: 17016436
The gene for E3 ubiquitin ligase WWP1 is located at 8q21, a region frequently amplified in human cancers, including prostate cancer. Recent studies have shown that WWP1 negatively regulates the...
10.
Quinn J, Brown L, Zhang J, Keller E, Vessella R, Corey E
Prostate Cancer Prostatic Dis
. 2005 Jul;
8(3):253-9.
PMID: 15999121
Zoledronic acid (ZA) has been shown to inhibit prostate tumor growth in vitro and have beneficial effects in patients with advanced prostate cancer (CaP). The aim of this study was...